Forage | $40,000,000 | (Jun 5, 2026)
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
Certified by Founder
Lodge
Remedy Plan Therapeutics
start up
United States
- Gaithersburg, MD
- 14/05/2025
- Unknown
- $18,000,000
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedy’s groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. We are advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
Remedy's lead asset is RPT1G. With a favorable efficacy and tolerability profile, RPT1G will be advancing to the clinic in 2024.
- Industry Biotechnology
- Website https://remedyplan.com/
- LinkedIn https://www.linkedin.com/company/remedy-plan/
ZutaCore | $100,000,000 | (Jun 5, 2026)
Terra AI | $20,000,000 | (Jun 5, 2026)
Town | $55,000,000 | (Jun 5, 2026)
Lassie | $35,000,000 | (Jun 5, 2026)
OFFROAD | $7,000,000 | (Jun 5, 2026)
Shifters | $10,200,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Scispot | $8,000,000 | (Jun 5, 2026)
Scotch | $20,000,000 | (Jun 5, 2026)